Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has granted inducement stock options to a new employee. The company awarded 130,000 options at an exercise price of $7.02 per share, matching the closing price on July 7, 2025.

The options, granted under Fulcrum's 2022 Inducement Stock Incentive Plan, have a ten-year term with a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.

CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employee 130,000 options to purchase shares of the company’s common stock at an exercise price of $7.02 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, July 7, 2025. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

What stock options did Fulcrum Therapeutics (FULC) grant to its new employee?

Fulcrum granted 130,000 stock options at an exercise price of $7.02 per share, with a ten-year term and four-year vesting schedule.

What is the vesting schedule for FULC's new employee stock options?

The options vest over four years, with 25% vesting after the first year and 6.25% vesting quarterly over the following three years.

When were the Fulcrum Therapeutics (FULC) inducement grants approved?

The grants were approved with an effective date of July 7, 2025, with the exercise price set at that day's closing price.

What is the purpose of Fulcrum's inducement stock option grants?

The options were granted as an inducement material for new employee recruitment, in accordance with Nasdaq Listing Rule 5635(c)(4).